from Wilson HTM this morning.
Eli Lilly reported Q4 AXIRON net sales of US$47.6m, which was ahead of our forecast of US$44m. Although US market prescriptions were down about 20% for the year, net sales of US$163.8m were down just 7.5% on the pcp, protected by price gains. If the FDA’s pending guidance on testosterone safety and utility proves benign, then we think the testosterone market can start improving again, if very modestly. Acrux price target is $1.25 (HOLD rated). Acrux reports its first-half results on Thursday, 26 February.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.524M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.5¢ | $19.90K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 463664 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 320000 | 2 |
View Market Depth
| Last trade - 15.56pm 25/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |